Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda commences phase III study of Amgen cancer drug

Takeda commences phase III study of Amgen cancer drug

15th April 2011

Takeda has begun a new phase III trial of a developmental cancer therapy created by fellow pharmaceutical company Amgen.

In association with its oncology subsidiary Millennium and the Takeda Bio Development Center, the firm has initiated a Japan-based study of AMG 479, a monoclonal antibody that targets the insulin-like growth factor 1 receptor.

The trial forms part of a global programme that is evaluating the compound as a treatment for metastatic pancreas cancer when compared to placebo, with overall survival being the primary endpoint.

It is hoped that the drug will offer a novel treatment option for pancreatic cancer, a form of the disease for which there are currently very few available therapies.

Dr Nancy Simonian, chief medical officer at Millennium, said: "We will accelerate the development of AMG 479 with the hope of providing it to patients and medical experts as soon as possible."

This comes after Millennium agreed a new collaboration with Sunesis Pharmaceuticals earlier this month that will aim to develop new cancer therapies based on kinase inhibitor research.ADNFCR-8000103-ID-800501457-ADNFCR

We currently have 7 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.